within Pharmacolibrary.Drugs.ATC.A;

model A10BJ07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0085,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BJ07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Beinaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the management of type 2 diabetes mellitus. It mimics endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon secretion, delay gastric emptying, and promote satiety. Approved in China for type 2 diabetes, not approved in US or EU.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on class data and limited public sources; beinaglutide is typically studied in healthy or type 2 diabetic adult populations after subcutaneous administration.</p><h4>References</h4><ol><li><p>Lin, P, et al., &amp; Cao, Y (2024). Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial. <i>Frontiers in pharmacology</i> 15 1433587–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2024.1433587\">10.3389/fphar.2024.1433587</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39239660/\">https://pubmed.ncbi.nlm.nih.gov/39239660</a></p></li><li><p>Young, MA, et al., &amp; Reinhardt, RR (2014). Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. <i>Postgraduate medicine</i> 126(7) 84–97. DOI:<a href=\"https://doi.org/10.3810/pgm.2014.11.2836\">10.3810/pgm.2014.11.2836</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25387217/\">https://pubmed.ncbi.nlm.nih.gov/25387217</a></p></li><li><p>Galloway, JA, &amp; Chance, RE (1994). Improving insulin therapy: achievements and challenges. <i>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</i> 26(12) 591–598. DOI:<a href=\"https://doi.org/10.1055/s-2007-1001766\">10.1055/s-2007-1001766</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7705765/\">https://pubmed.ncbi.nlm.nih.gov/7705765</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BJ07;
